26.61

0.45% -0.12

After Hours: 26.69 0.08 +0.30%

Damora Therapeutics Inc (DMRA)

Overview News Price History Discussions Forecast

Damora Therapeutics Inc stock is traded at $26.61, with a volume of 293.20K. It is down -0.45% in the last 24 hours and up +1.06% over the past month. Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Previous Close:

$26.73

Open:

$26.75

24h Volume:

293.20K

Relative Volume:

2.64

Market Cap:

$1.60B

Revenue:

Net Income/Loss:

$-209.84M

P/E Ratio:

-5.8228

EPS:

-4.57

Net Cash Flow:

$-6.73M

1W Performance:

+3.95%

1M Performance:

+1.06%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$25.92

$27.18

1-Week Range:

$24.80

$28.57

52-Week Range:

$16.50

$28.57

Damora Therapeutics Inc Stock (DMRA) Company Profile

Name

Damora Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(781) 281-9020

Address

221 CRESCENT STREET, WALTHAM

Employee

Twitter

Next Earnings Date

2026-03-18

Latest SEC Filings

DMRA's Discussions on Twitter

Compare DMRA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMRA Damora Therapeutics Inc	26.61	1.61B	0	-209.84M	-6.73M	-4.57
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-25-26	Initiated	Evercore ISI	Outperform
Feb-17-26	Initiated	UBS	Buy
Jan-07-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Initiated	Guggenheim	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Nov-23-20	Initiated	BofA Securities	Buy
Nov-23-20	Initiated	Credit Suisse	Outperform
Nov-23-20	Initiated	SVB Leerink	Outperform

View All

Damora Therapeutics Inc Stock (DMRA) Latest News

Apr 15, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Forecast and Price Target 2026 - MarketBeat

Apr 15, 2026

Apr 14, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat

Apr 14, 2026

Apr 13, 2026

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat

Apr 13, 2026

Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat

Apr 13, 2026

Apr 11, 2026

Certain Warrants of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026. - marketscreener.com

Apr 11, 2026

Certain Stock Options of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026. - marketscreener.com

Apr 11, 2026

Certain Common Stock of Galecto, Inc. are subject to a Lock-Up Agreement Ending on 12-APR-2026. - marketscreener.com

Apr 11, 2026

Is Damora Therapeutics’ (DMRA) New CEO and Fast Track Status Reframing Its Pipeline Execution Story? - Sahm

Apr 11, 2026

Apr 10, 2026